Profit Warnings & Scientific Advice

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, the HCA profit warning has been top of mind since this morning. The signals are getting louder.

MarcusSame here. We're looking at HCA's profit warning and what it signals for US healthcare access — the system strain is undeniable. Then subcutaneous Leqembi's approval and how it's reshaping Alzheimer's value narratives. And the FTC-CVS insulin settlement — a real moment for PBM transparency. Plus ICER's expansion of early-phase scientific advice.

SaraThat first one hits close to home — the budget impact ripple effects from hospital consolidation are something payers can't ignore. We're seeing real erosion in sustainable access.

MarcusExactly. Let's get into it.

MarcusKicking off with HCA's profit warning — their largest in over a decade. The immediate takeaway is the pressure on hospital margins from uncompensated care and reimbursement delays. But what's striking is how this reflects broader systemic strain.

SaraAbsolutely. And from a payer perspective, this isn't just about one system. It's the canary in the coal mine for access erosion. When hospital margins tighten, we see downstream effects on formulary negotiations and patient assistance programs.

MarcusThat connects to something I keep coming back to — the innovation paradox. We're developing incredible therapies, but the delivery infrastructure is fraying. The R&D investment argument gets harder when the system itself is under such stress.

SaraI'd push back slightly on that — the R&D argument stands, but we need better integration between development and delivery planning. What's interesting is how this intersects with the IRA's inflation rebates creating cash flow volatility.

MarcusFair point. The part that gives me pause is the lack of coordinated response. We're seeing fragmented solutions when we need systemic alignment. The patient perspective here is crucial — delays in care cascade into worse outcomes.

SaraExactly. And that's where budget impact becomes more than just a spreadsheet — it's about the opportunity cost of not addressing these structural issues. The field hasn't fully modeled the compounding effect.

MarcusRight. And from the payer side, the question becomes: how do we preserve access while managing sustainability? It's a tension without easy answers.

MarcusMoving to subcutaneous Leqembi — the FDA approval for the subcutaneous formulation. This is a significant step for Alzheimer's treatment, reducing administration burden from two hours to five minutes.

SaraThat's one read — I'd frame it slightly differently. The administration cost reduction is real, but the value proposition hinges on comparative effectiveness data. What we don't yet know is how this shifts the cost-benefit equation for payers.

MarcusThat's fair, though I think payers would see it as an incremental improvement. The real story is the precedent it sets for neurodegenerative disease treatments — faster administration could enable earlier intervention, which may alter the value profile.

SaraWhat strikes me about that is the unmet need versus cost dynamic. Alzheimer's therapies face unique value assessments, and this formulation change might not move the needle on efficacy. The budget impact question remains unresolved.

MarcusI wonder if that's the full picture though — the patient burden reduction has indirect value. Fewer hours tied to infusion means more quality time, which HEOR models struggle to quantify but payers increasingly recognize.

SaraThe part that gives me pause is the precedent for reformulation-driven pricing. If this becomes the norm, it could inflate prices without incremental therapeutic benefit. That's a concern for system sustainability.

MarcusExactly. And that connects to the broader HEOR challenge: how do we capture real-world value that isn't captured in traditional endpoints? This is one of those stories where the market access strategy will be as critical as the clinical data.

MarcusThe FTC settlement with CVS Caremark over insulin pricing practices — $650 million to resolve allegations of unfair practices. This is more than a fine; it's a signal about PBM transparency.

SaraThat's a significant development. The core issue here is the lack of transparency in rebate structures. For payers, this settlement exposes how PBM practices can undermine insulin affordability despite list price caps.

MarcusI'd push back slightly on that framing — while transparency is key, the settlement addresses specific anti-competitive behaviors. The broader implication is the scrutiny on PBMs' role in insulin access, which could reshape formulary negotiations.

SaraWhat strikes me about that is the opportunity cost angle. When PBMs engage in these practices, it diverts resources from other value-based interventions. The budget impact extends beyond insulin to the entire diabetes care ecosystem.

MarcusRight. And from the R&D side, this creates a more predictable environment for insulin developers. If the market becomes more transparent, it could support sustainable innovation in this space.

SaraThe part that gives me pause is the enforcement gap. One settlement doesn't systemic change. We need consistent regulatory oversight to prevent these practices from evolving into new forms.

MarcusExactly. And that's where the patient perspective is non-negotiable — insulin access isn't a theoretical budget line; it's a daily necessity. This settlement might be a step toward restoring trust in the system.

MarcusICER's expansion of early-phase scientific advice to include Phase I/II data. This is a strategic shift toward de-risking development before Phase III.

SaraThat's a significant evolution. For payers, this could mean earlier engagement with value proposition development, but it also raises questions about the maturity of evidence at this stage.

MarcusI'd frame it as a pragmatic response to development failures. By getting HEOR perspectives earlier, sponsors can realign trials around endpoints that matter for access. The question is whether payers can provide meaningful input with limited data.

SaraWhat strikes me about that is the resource implication. HTA bodies don't have capacity to review Phase I data meaningfully. This could create bottlenecks unless they streamline processes.

MarcusThe part that gives me pause is the signal this sends to developers. If early advice becomes too influential, it might stifle innovation by pushing toward incremental improvements rather than breakthroughs. That's a tension worth watching.

SaraExactly. And that connects to the patient perspective — we need both innovation and timely access. This expansion aims to bridge that gap, but the proof will be in how it's implemented.

MarcusRight. From the payer side, the key will be ensuring this doesn't create two-tiered advice processes. Consistency across development phases is critical for credibility.

SaraA lot to think about today. I'll be watching how the HCA warning influences hospital-payer negotiations on value-based contracts.

MarcusSame — and for me the thread running through today is the growing pressure on market access strategies to balance innovation, sustainability, and patient needs. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.